Protein detail

CD4

T-cell surface glycoprotein CD4 (T-cell surface antigen T4/Leu-3) (CD antigen CD4)

Entry name
CD4
UniProt ID
EVMP confidence score
0.53
Supporting publications (n)
5
Transmembrane count
1
Protein classification
CD markersDisease related genesFDA approved drug targetsHuman disease related genesPredicted intracellular proteinsPredicted membrane proteinsTransporters
Basic Information
Protein Names
T-cell surface glycoprotein CD4 (T-cell surface antigen T4/Leu-3) (CD antigen CD4)
Protein Class (7)
CD markersDisease related genesFDA approved drug targetsHuman disease related genesPredicted intracellular proteinsPredicted membrane proteinsTransporters
Protein Function (6)
  • Predicted intracellular proteins
  • CD markers
  • Human disease related genes:Immune system diseases:Primary immunodeficiency
  • Transporters:Accessory Factors Involved in Transport
  • Disease related genes
  • FDA approved drug targets:Biotech drugs
Transmembrane
397..418; Helical
Transmembrane Count
1
Entrez Gene Symbol
Gene Description
CD4 molecule
Chromosome
12
Position
6786858-6820799
Supporting publications (n)
5
EVMP confidence score
0.53
Fluorescence & Localization
CD4 fluorescence
Cell SpecificRetinal amacrine cellsSingle-Nuclei Brain Specificcerebellar inhibitory
Function & Pathway
Protein Function (6)
  • Predicted intracellular proteins
  • CD markers
  • Human disease related genes:Immune system diseases:Primary immunodeficiency
  • Transporters:Accessory Factors Involved in Transport
  • Disease related genes
  • FDA approved drug targets:Biotech drugs
Mediation Categories (5)
Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediationImmune mediationReceptor-signaling mediation
Relations & Evidence144

Enzyme-Mediated Modification (3)

3 records.

Substrate Gene SymbolEnzyme Gene SymbolEnzyme UniProt IDResidue TypeResidue OffsetModificationDatabaseReferences
CD4PRKCAP17252S440phosphorylationPhosphoSite_MIMPMIMPProtMapperPhosphoSitePhosphoSite_ProtMapper
CD4PRKCAP17252S433phosphorylationphosphoELM_MIMPPhosphoSite_MIMPMIMPProtMapperPhosphoSitePhosphoSite_ProtMapper
CD4PRKCQQ04759S433phosphorylationREACH_ProtMapperProtMapperProtMapper:19050241

Ligand-Receptor Signaling (49)

49 records.

CategoryParentDatabaseTransmitterReceiverSecretedPlasma Membrane (Transmembrane)Plasma Membrane (Peripheral)
receptorreceptorGO_IntercellYesYes
receptorreceptorICELLNETYesYes
receptorreceptorCellChatDBYesYes
receptorreceptorCellTalkDBYesYes
receptorreceptorRamilowski2015YesYes
receptorreceptorKirouac2010YesYes
receptorreceptorLRdbYesYes
receptorreceptorBaccin2019YesYes
interleukinreceptorBaccin2019YesYes
cytokinereceptorICELLNETYesYes
Page 1 of 5Next

Regulatory Interaction Network (64)

64 records.

Source Protein SymbolSource UniProt IDTarget Protein SymbolTarget UniProt IDIs DirectedIs StimulationIs InhibitionDatabaseReferences
COMPLEX:CHEBI:166824_CHEBI:53000_P01911_P28067CD4P01730YesYesSIGNORSIGNOR:31001252
COMPLEX:CHEBI:166824_CHEBI:53000_P01920_P06340CD4P01730YesYesSIGNORSIGNOR:31001252
COMPLEX:CHEBI:166824_CHEBI:53000_P01903_Q30154CD4P01730YesYesSIGNORSIGNOR:31001252
COMPLEX:CHEBI:166824_CHEBI:53000_P01903_P13762CD4P01730YesYesSIGNORSIGNOR:31001252
COMPLEX:CHEBI:166824_CHEBI:53000_P13765_P28067CD4P01730YesYesSIGNORSIGNOR:31001252
COMPLEX:CHEBI:166824_CHEBI:53000_P13762_P28067CD4P01730YesYesSIGNORSIGNOR:31001252
COMPLEX:CHEBI:166824_CHEBI:53000_P28067_Q30154CD4P01730YesYesSIGNORSIGNOR:31001252
COMPLEX:CHEBI:166824_CHEBI:53000_P01906_P05538CD4P01730YesYesSIGNORSIGNOR:31001252
COMPLEX:CHEBI:166824_CHEBI:53000_P01911_P20036CD4P01730YesYesSIGNORSIGNOR:31001252
COMPLEX:CHEBI:166824_CHEBI:53000_P01909_P79483CD4P01730YesYesSIGNORSIGNOR:31001252
Page 2 of 7PreviousNext

Protein Complex Composition (27)

27 records.

Component NameComponent Gene SymbolsComponent UniProt IDStoichiometryDatabaseDatabase IDsReferences
CD44-ERK1-ERK2-RHAMM complexCD44HMMRMAPK1MAPK3O75330P16070P27361P284820:0:0:0CORUMCORUM:750417392272
Cd74-Cd44 receptor complexCD44CD74P04233P160701:1CellinkerCompleatCellChatDBCompleat:HC6218056708
Interleukin-16 receptor-ligand complexCD4IL16P01730Q140051:1ComplexPortalintact:EBI-5504135627231345942278096996301475529210809960
ABCD4DEPDC1FAM234BFRMD5LAPTM4ARUSF1TMEM214A2RU67O14678Q15012Q5TB30Q6NUQ4Q7Z6J6Q96GQ50:0:0:0:0:0:0hu.MAP2
ABCD4DEPDC1FAM234BFRMD5LAPTM4ARUSF1A2RU67O14678Q15012Q5TB30Q7Z6J6Q96GQ50:0:0:0:0:0hu.MAP2
ABCD4FAM234BFRMD5LAPTM4AA2RU67O14678Q15012Q7Z6J60:0:0:0hu.MAP2
ABCD4FAM234BFRMD5A2RU67O14678Q7Z6J60:0:0hu.MAP2
ABCD4O146782PDBPDB:6jbj
BLTP1BTRCGLI3PDCD4SLC16A4O15374P10071Q2LD37Q53EL6Q9Y2971:1:1:1:1NetworkBlastCompleatCompleat:HC4003
FAM114A2HSPA12APDCD4RAB5IFTMEM51O43301Q53EL6Q9BUV8Q9NRY5Q9NW970:0:0:0:0hu.MAP
Page 1 of 3Next

Isolation & Detection Technology (1)

1 record.

EV Isolation MethodDetection MethodNumber of ReferencesReferences
Differential UltracentrifugationSize Exclusion ChromatographyWestern blotting130646616
Sequence, Structure & Domains

Sequences

Length
458
Mass
51,111
Sequence
MNRGVPFRHLLLVLQLALLPAATQGKKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICEVEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPSVQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKKVEFKIDIVVLAFQKASSIVYKKEGEQVEFSFPLAFTVEKLTGSGELWWQAERASSSKSWITFDLKNKEVSVKRVTQDPKLQMGKKLPLHLTLPQALPQYAGSGNLTLALEAKTGKLHQEVNLVVMRATQLQKNLTCEVWGPTSPKLMLSLKLENKEAKVSKREKAVWVLNPEAGMWQCLLSDSGQVLLESNIKVLPTWSTPVQPMALIVLGGVAGLLLFIGLGIFFCVRCRHRRRQAERMSQIKRLLSEKKTCQCPHRFQKTCSPI

3D Structural Models

Turn
75..79
Helix
84..89; 101..103; 176..178; 398..421; 432..438
Beta Strand
27..32; 37..39; 44..47; 51..55; 56..58; 60..63; 68..71; 94..96; 105..111; 114..128; 131..134; 135..137; 139..144; 152..156; 158..160; 162..172; 180..188; 191..199; 200..202; 426..428; 440..442
3D Structure
Electron microscopy (29); NMR spectroscopy (3); X-ray crystallography (50)

Domain & Motif Annotations

Domain (CC)
The Ig-like V-type domain mediates the interaction with MHCII.
Domain (FT)
26..125; Ig-like V-type; 126..203; Ig-like C2-type 1; 204..317; Ig-like C2-type 2; 318..374; Ig-like C2-type 3
Region
427..455; HIV-1 Vpu-susceptibility domain
Clinical Relevance
Disease Involvement
FDA approved drug targets
Biomarker
Phase 3; Phase 2; Approved; Phase 1; Discontinued in Phase 2; Investigative
Drug Targets
FDA approved drug targets
Interaction Protein
ENSG00000182866
Interaction Count
1
Interaction Dataset
intact_biogrid
Supporting Publications5
PMIDTitleRelated sentences
36982991Extracellular Vesicles of COVID-19 Patients Reflect Inflammation, Thrombogenicity, and Disease Severity.Severe patients' EVs displayed higher percentages of small EVs (<150 nm) with increased expression of exosome marker CD63.
37499326Exosomal PD-L1 derived from head and neck squamous cell carcinoma promotes immune evasion by activating the positive feedback loop of activated regulatory T cell-M2 macrophage.Herein, we investigated the effect of PD-L1 carried on exosomes derived from tumor cells (TEXs) on the aTreg-M2 positive feedback loop, as well as their role in mediating immunosuppression.
37531777Multifunctional hybrid exosomes enhanced cancer chemo-immunotherapy by activating the STING pathway.Herein, multifunctional hybrid exosomes for cGAS/STING activation are designed by fusing genetically engineered exosomes carrying CD47 derived from tumor cells with exosomes from M1 macrophages, which are further encapsulated with DNA-targeting agent (SN38) and STING-agonist (MnO Copyright © 2023 Elsevier Ltd. All rights reserved.
37612209Mechanism of exosomes from adipose-derived mesenchymal stem cells on sepsis-induced acute lung injury by promoting TGF-β secretion in macrophages.No related sentences available
38902710Exosomes multiplex profiling, a promising strategy for early diagnosis of laryngeal cancer.Circulating exosomes were collected from serum collected from 30 LCa patients and 20 healthy volunteers by the use of antibody affinity method exploiting CD63 specific surface marker.